A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Gout Clinical Trial

Official title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC-201 IN SUBJECTS WITH GOUT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02287818
• Other study ID #: AC-201-GOU-002
• Status: Completed
• Phase: Phase 2
• Start date: December 2014
• Est. completion date: October 27, 2016

Study information

• Verified date: June 2022
• Source: TWi Biotechnology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of gout flares during ULT.

Description:

AC-201CR is a control released formulation of AC-201 that in previous clinical studies showed potential dual effects in both reducing serum uric acid (sUA) and gout flares. The mechanism of action of AC-201 includes the inhibition of the production and activity of caspase-1 and interleukin-1β (IL-1β), and selective inhibition of re-absorption transporters in the kidney. The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit while avoiding acute gout flares. However, the initiation of urate-lowering therapy (ULT) increases the occurrence of acute gouty arthritis flares. IL-1β plays a key role in mediating this inflammatory response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 127
• Est. completion date: October 27, 2016
• Est. primary completion date: October 27, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female age 20 to 65 years, inclusive.

2. Meets =6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout (Appendix 2), OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid.

3. Serum uric acid =7.5 mg/dL and =10 mg/dL at screening with =1 gouty arthritis flare within one year prior to screening, OR serum uric acid =9 mg/dL and =10 mg/dL at screening with or without prior gout flares.

Exclusion Criteria:

1. Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2 weeks prior to screening.

2. Occurrence of a gouty arthritis flare within 1 week prior to screening or during the screening period through baseline.

3. Use of colchicine within 1 week prior to screening.

4. Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.

5. Allergy, contraindication, or intolerance to febuxostat.

6. Severe renal impairment.

7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration >2 times the upper limit of laboratory normal range (>2x ULN) at screening.

Related Conditions & MeSH terms

• Gout

Intervention

Drug:
• Placebo
Placebo twice daily from Day 1 to Week 12
• AC-201
AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
• Febuxostat
Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL

Locations

Country	Name	City	State
Taiwan	Taipei Veteran General Hospital (TVGH)	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
TWi Biotechnology, Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL		8 weeks